PL188537B1 - Szczepionka nowotworowa i sposób jej wytwarzania - Google Patents
Szczepionka nowotworowa i sposób jej wytwarzaniaInfo
- Publication number
- PL188537B1 PL188537B1 PL96326756A PL32675696A PL188537B1 PL 188537 B1 PL188537 B1 PL 188537B1 PL 96326756 A PL96326756 A PL 96326756A PL 32675696 A PL32675696 A PL 32675696A PL 188537 B1 PL188537 B1 PL 188537B1
- Authority
- PL
- Poland
- Prior art keywords
- cells
- tumor
- patient
- peptides
- peptide
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims abstract description 62
- 230000003217 anti-cancerogenic effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 235
- 210000004027 cell Anatomy 0.000 claims abstract description 158
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 135
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 103
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 94
- 229920000656 polylysine Polymers 0.000 claims abstract description 19
- 210000000987 immune system Anatomy 0.000 claims abstract description 17
- 108010039918 Polylysine Proteins 0.000 claims abstract description 14
- 230000024932 T cell mediated immunity Effects 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 9
- 239000000427 antigen Substances 0.000 claims description 72
- 102000036639 antigens Human genes 0.000 claims description 70
- 108091007433 antigens Proteins 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 229940022399 cancer vaccine Drugs 0.000 claims description 36
- 238000009566 cancer vaccine Methods 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 31
- 239000003446 ligand Substances 0.000 claims description 21
- 102000054766 genetic haplotypes Human genes 0.000 claims description 19
- 230000028993 immune response Effects 0.000 claims description 17
- 108010002350 Interleukin-2 Proteins 0.000 claims description 16
- 230000000735 allogeneic effect Effects 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 230000002163 immunogen Effects 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 210000004443 dendritic cell Anatomy 0.000 claims description 9
- 210000002950 fibroblast Anatomy 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 8
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108010067390 Viral Proteins Proteins 0.000 claims description 5
- 210000005170 neoplastic cell Anatomy 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 108010077805 Bacterial Proteins Proteins 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 230000006800 cellular catabolic process Effects 0.000 claims description 3
- 239000007857 degradation product Substances 0.000 claims description 3
- 108700010900 influenza virus proteins Proteins 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 102000000588 Interleukin-2 Human genes 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 9
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 8
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 8
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 239000012581 transferrin Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 5
- 102000004338 Transferrin Human genes 0.000 description 5
- 108090000901 Transferrin Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000005809 anti-tumor immunity Effects 0.000 description 4
- 229940030156 cell vaccine Drugs 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101800001271 Surface protein Proteins 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 208000014061 Extranodal Extension Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940115256 melanoma vaccine Drugs 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- -1 that is Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DMSDCBKFWUBTKX-UHFFFAOYSA-N 2-methyl-1-nitrosoguanidine Chemical compound CN=C(N)NN=O DMSDCBKFWUBTKX-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 210000003359 CD4-positive helper T lymphocyte Anatomy 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 239000004471 Glycine Chemical group 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010014597 HLA-B44 Antigen Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 108010080632 MUT 1 peptide Proteins 0.000 description 1
- 108010081053 MUT 2 peptide Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000021 endosomolytic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000002861 immature t-cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 1
- 108010060175 trypsinogen activation peptide Proteins 0.000 description 1
- 229940030325 tumor cell vaccine Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19543649A DE19543649C2 (de) | 1995-11-23 | 1995-11-23 | Tumorvakzine und Verfahren zu ihrer Herstellung |
| DE19607044A DE19607044A1 (de) | 1996-02-24 | 1996-02-24 | Tumorvakzine und Verfahren zu ihrer Herstellung |
| PCT/EP1996/005126 WO1997019169A1 (de) | 1995-11-23 | 1996-11-21 | Tumorvakzine und verfahren zu ihrer herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL326756A1 PL326756A1 (en) | 1998-10-26 |
| PL188537B1 true PL188537B1 (pl) | 2005-02-28 |
Family
ID=26020603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL96326756A PL188537B1 (pl) | 1995-11-23 | 1996-11-21 | Szczepionka nowotworowa i sposób jej wytwarzania |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20020085997A1 (enExample) |
| EP (1) | EP0866851A1 (enExample) |
| JP (1) | JP2000502052A (enExample) |
| KR (1) | KR19990067653A (enExample) |
| CN (1) | CN1202931A (enExample) |
| AR (1) | AR004341A1 (enExample) |
| AU (1) | AU720131B2 (enExample) |
| BG (1) | BG62999B1 (enExample) |
| BR (1) | BR9611466A (enExample) |
| CA (1) | CA2238176A1 (enExample) |
| CO (1) | CO4520254A1 (enExample) |
| CZ (1) | CZ158998A3 (enExample) |
| EE (1) | EE03778B1 (enExample) |
| HU (1) | HUP0000318A3 (enExample) |
| NO (1) | NO982329D0 (enExample) |
| NZ (1) | NZ322910A (enExample) |
| PL (1) | PL188537B1 (enExample) |
| RO (1) | RO115275B1 (enExample) |
| RU (1) | RU2206329C2 (enExample) |
| SK (1) | SK66998A3 (enExample) |
| TR (1) | TR199800912T2 (enExample) |
| TW (1) | TW514530B (enExample) |
| UY (2) | UY24367A1 (enExample) |
| WO (1) | WO1997019169A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4600681A1 (es) † | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
| CA2278678A1 (en) * | 1997-01-31 | 1998-08-06 | Research Corporation Technologies, Inc. | Cancer immunotherapy with semi-allogeneic cells |
| EP0904786B1 (en) * | 1997-08-22 | 2004-12-15 | Science Park Raf S.p.A. | Tumor vaccination by use of autologous or HLA-related antigen presenting cell (APC) transduced with a tumour antigen and a foreign antigen capable of causing an immune reaction |
| US7014848B1 (en) | 1998-03-20 | 2006-03-21 | Genzyme Corporation | Enhanced anti-tumor immunity |
| CA2322660A1 (en) * | 1998-03-20 | 1999-09-23 | Genzyme Corporation | Enhanced anti-tumor immunity |
| FR2807661A1 (fr) * | 2000-04-14 | 2001-10-19 | Univ Nantes | Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus |
| EP1473564A4 (en) * | 2001-09-18 | 2008-12-10 | Greenpeptide Co Ltd | METHOD FOR DETECTING CELL IMMUNITY AND ITS APPLICATION TO MEDICAMENTS |
| RU2203683C1 (ru) * | 2001-09-20 | 2003-05-10 | НИИ онкологии им. проф. Н.Н. Петрова | Способ иммунотерапии костно-мозговыми дендритными клетками больных солидными опухолями |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| CN1315536C (zh) * | 2002-09-13 | 2007-05-16 | 李进 | 肿瘤抗原疫苗及其制备方法和疫苗组合物 |
| GB0224442D0 (en) | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| EP1667711B1 (en) * | 2003-08-25 | 2010-07-28 | UniVax, LLC | Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris) |
| RU2267326C2 (ru) * | 2004-03-16 | 2006-01-10 | ГУН НИИ онкологии им. проф. Н.Н. Петрова Минздрава РФ | Способ иммунотерапии опухолевым лизатом с адъювантом беталейкин больных солидными опухолями |
| US7674456B2 (en) * | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| CN101163503B (zh) * | 2005-02-23 | 2013-05-08 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
| US20090214494A1 (en) * | 2005-03-29 | 2009-08-27 | The Board Of Trustees Of The University Of Illinoi | Cancer Vaccines and Therapeutic Methods |
| DK1760088T3 (da) * | 2005-09-05 | 2008-06-09 | Immatics Biotechnologies Gmbh | Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| WO2011101465A1 (en) | 2010-02-19 | 2011-08-25 | Intercell Ag | Ic31 nanoparticles |
| AU2013289939B2 (en) * | 2012-07-12 | 2018-08-09 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
| JP6710004B2 (ja) | 2016-03-15 | 2020-06-17 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計 |
| WO2018208856A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| KR20220016137A (ko) | 2019-05-30 | 2022-02-08 | 그릿스톤 바이오, 인코포레이티드 | 변형된 아데노바이러스 |
| WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
| CA3211645A1 (en) * | 2021-03-12 | 2022-09-15 | Erika VON EUW | Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235525B1 (en) * | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
| JPH05246889A (ja) * | 1992-03-05 | 1993-09-24 | Seitai Chiyousetsu Kenkyusho:Kk | 制癌方法および制癌剤 |
| EP0569678A3 (de) * | 1992-03-13 | 1994-10-26 | Yeda Res & Dev | Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen. |
-
1996
- 1996-11-19 UY UY24367A patent/UY24367A1/es not_active IP Right Cessation
- 1996-11-21 US US09/077,214 patent/US20020085997A1/en not_active Abandoned
- 1996-11-21 HU HU0000318A patent/HUP0000318A3/hu unknown
- 1996-11-21 RU RU98111622/14A patent/RU2206329C2/ru not_active IP Right Cessation
- 1996-11-21 EP EP96939870A patent/EP0866851A1/de not_active Withdrawn
- 1996-11-21 SK SK669-98A patent/SK66998A3/sk unknown
- 1996-11-21 JP JP9519395A patent/JP2000502052A/ja not_active Abandoned
- 1996-11-21 CN CN96198493A patent/CN1202931A/zh active Pending
- 1996-11-21 AU AU76947/96A patent/AU720131B2/en not_active Ceased
- 1996-11-21 WO PCT/EP1996/005126 patent/WO1997019169A1/de not_active Ceased
- 1996-11-21 PL PL96326756A patent/PL188537B1/pl not_active IP Right Cessation
- 1996-11-21 CA CA002238176A patent/CA2238176A1/en not_active Abandoned
- 1996-11-21 CZ CZ981589A patent/CZ158998A3/cs unknown
- 1996-11-21 RO RO98-00985A patent/RO115275B1/ro unknown
- 1996-11-21 NZ NZ322910A patent/NZ322910A/xx unknown
- 1996-11-21 TR TR1998/00912T patent/TR199800912T2/xx unknown
- 1996-11-21 EE EE9800161A patent/EE03778B1/xx not_active IP Right Cessation
- 1996-11-21 BR BR9611466A patent/BR9611466A/pt not_active Application Discontinuation
- 1996-11-21 KR KR1019980703681A patent/KR19990067653A/ko not_active Ceased
- 1996-11-22 AR ARP960105291A patent/AR004341A1/es not_active Application Discontinuation
- 1996-11-22 CO CO96061701A patent/CO4520254A1/es unknown
- 1996-11-23 TW TW085114455A patent/TW514530B/zh not_active IP Right Cessation
-
1997
- 1997-01-03 UY UY24430A patent/UY24430A1/es not_active IP Right Cessation
-
1998
- 1998-05-08 BG BG102439A patent/BG62999B1/bg unknown
- 1998-05-22 NO NO982329A patent/NO982329D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0000318A2 (hu) | 2000-06-28 |
| EE03778B1 (et) | 2002-06-17 |
| AR004341A1 (es) | 1998-11-04 |
| PL326756A1 (en) | 1998-10-26 |
| BG102439A (en) | 1999-01-29 |
| UY24430A1 (es) | 1997-07-01 |
| RO115275B1 (ro) | 1999-12-30 |
| AU720131B2 (en) | 2000-05-25 |
| EP0866851A1 (de) | 1998-09-30 |
| BG62999B1 (bg) | 2001-01-31 |
| TR199800912T2 (xx) | 1998-08-21 |
| AU7694796A (en) | 1997-06-11 |
| US20020085997A1 (en) | 2002-07-04 |
| RU2206329C2 (ru) | 2003-06-20 |
| TW514530B (en) | 2002-12-21 |
| CN1202931A (zh) | 1998-12-23 |
| CA2238176A1 (en) | 1997-05-29 |
| BR9611466A (pt) | 1999-05-18 |
| UY24367A1 (es) | 2000-10-31 |
| HUP0000318A3 (en) | 2002-02-28 |
| CZ158998A3 (cs) | 1999-06-16 |
| WO1997019169A1 (de) | 1997-05-29 |
| NZ322910A (en) | 2000-05-26 |
| EE9800161A (et) | 1998-12-15 |
| CO4520254A1 (es) | 1997-10-15 |
| SK66998A3 (en) | 1998-12-02 |
| NO982329D0 (no) | 1998-05-22 |
| JP2000502052A (ja) | 2000-02-22 |
| KR19990067653A (ko) | 1999-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL188537B1 (pl) | Szczepionka nowotworowa i sposób jej wytwarzania | |
| US7105162B1 (en) | Pharmaceutical composition for immunomodulation based on peptides and adjuvants | |
| ES2357960T3 (es) | Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos. | |
| JP5127224B2 (ja) | 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法 | |
| Minev et al. | Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice | |
| CA2331378A1 (en) | Vaccination strategy to prevent and treat cancers | |
| IL184273A (en) | Use of entraining and amplifying compositions in the manufacture of a medicament for immunization and a set of immunogenic compositions for inducing an immune response in a mammal | |
| US8895017B2 (en) | HER-2 peptides and vaccines | |
| CN102172397A (zh) | 树突细胞的体内靶向 | |
| MXPA98003930A (en) | Vaccines against tumors and procedure for your producc | |
| Bonnefoy et al. | Cancer Vaccine Design: A Novel Bacterial | |
| Brandt | Peptide Vaccines | |
| Yang et al. | Peptide Vaccines | |
| Elamanchili | Antigen delivery to dendritic cells using biodegradable poly (D, L-lactic-co-glycolic acid) nanoparticles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20051121 |